百奥泰(688177.SH)：与 Hikma Pharmaceuticals USAInc.就BAT2206（乌司奴单抗）注射液签署授权许可与商业化协议收到里程碑付款

Core Viewpoint - The company received a milestone payment of $10 million from Hikma, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The $10 million payment will be credited after deducting bank fees, contributing positively to the company's financial position [1] Group 2: Product Development - The company's product BAT2206 (Ustinumab injection) has received approvals from both the FDA and EMA, with the U.S. brand name being STARJEMZA® and the European brand name Usymro® [1] - A marketing application for BAT2206 has been submitted to the National Medical Products Administration (NMPA) and is currently under review [1]